Subclinical atherosclerosis in systemic lupus erythematosus (SLE): The relative contribution of classic risk factors and the lupus phenotype

Rheumatology

Volumn 46, Issue 6, 2007, Pages 983-988

  Ahmad, Y ^a,b   Shelmerdine, J ^a   Bodill, H ^b   Lunt, M ^b   Pattrick, M G ^c   Teh, L S ^d   Bernstein, R M ^a   Walker, M G ^b   Bruce, Ian N ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^d ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Risk factors; Smoking; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; STEROID; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B SCAN; CARDIOVASCULAR RISK; CAROTID ARTERY; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HIGH RISK POPULATION; HUMAN; INTERNAL CAROTID ARTERY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGE FACTORS; ATHEROSCLEROSIS; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 34447326143     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem002     Document Type: Article

References (32)

1. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997;145:400-15.
2. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003;349:2399-406.
3. Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus arythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000;27:2372-7.
4. El Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399-404.
5. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
6. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93:513-9.
7. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
8. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Eng J Med 2005;352:1685-95.
9. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-73.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic kipus erythematosus. Arthritis Rheum 1997;40:1725.
11. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
12. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus. erythematosus. Arthritis Rheum 1997;40:809-13.
13. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
14. Sidhu PS, Desai SR. A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. Br J Radiol 1997;70:85-9.
15. Li R, Duncan BB, Metcalf PA et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994;25:2377-83.
16. Hanley JA, McNeill BJ. The meaning and use of the area under a receiver operating characteristic 'ROC' curve. Radiology 1982;143:29-36.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44:837-45.
18. Durrington PN. Risk in cardiovascular disease. Joint British Societies recommend their computer program for risk calculations. Br Med J 2000;321:174-5.
19. Asanuma Y, Oeser A, Shintani AK et al. Premature ooronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003;349:2407-15.
20. Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104; 1887-93.
21. Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071-7.
22. Tolaza SM. Uribe AG, McGwin G, Jr et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:947-57.
23. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipents. Transplantation 1998; 66:507-15.
24. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1566-74.
25. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity, between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.' Rheumatology 2003;42:893-9.
26. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002;11:208-14.
27. Nicolo D. Goldman BI, Monestier M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 2003;48:2974-8.
28. Van Oostrum AJHHM, van Wijk JPH, Cabezas MC. Lipaemia, inflammation and atherosclerosis: Novel opportunities in the understanding and treatment of atherosclerosis. Drugs 2004;64:19-41.
29. Huang ZS, Jeng JS, Wang CH, Yip PK, Wu TH, Lee TK. Correlations between peripheral differential leukocyte counts and carotid atherosclerosis in non-smokers. Atherosclerosis 2001;158:431-6.
30. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, Manzi S. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004;50:151-9.
31. Tell GS, Howard G, McKinney WM. Risk factors for site specific extracranial carotid artery plaque distribution as measured by B-mode ultrasound. J Clin Epidemiol 1989;42:551-9.
32. Crouse JR, Goldhourt U, Evans G et al. Risk factors and segment-specific carotid arterial enlargement in the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1996;27:69-75.